Literature DB >> 10773049

Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.

J de Wildt-Eggen1, S Nauta, J G Schrijver, M van Marwijk Kooy, M Bins, H C van Prooijen.   

Abstract

BACKGROUND: Reactions after platelet transfusions are rather common and frequently are caused by plasma constituents. In recent developments, the preparation and storage of platelet concentrates (PCs) in a platelet additive solution (PAS-2) have been shown to result in acceptable storage conditions. A major drawback of the use of these PCs is the progressive increase of P-selectin-positive platelets during storage. The clinical benefit of transfusions of PCs in PAS-2 was studied. STUDY DESIGN AND METHODS: PCs prepared from buffy coats were suspended in either plasma or PAS-2 and stored for up to 5 days. Clinical responses were evaluated in a prospective study in 21 patients treated with intensive chemotherapy for hematologic malignancies. Eligible patients were randomly assigned to receive prophylactic transfusions of PCs prepared in either plasma or PAS-2. Reactions and CCIs were recorded after each transfusion.
RESULTS: The incidence of reactions in 12 patients given PCs in plasma (n = 192) was 12 percent. Transfusions to 9 patients of PCs in PAS-2 (n = 132) showed a reduction in the incidence of reactions to 5.3 percent (p<0.05). The average 1-hour and 20-hour CCIs after transfusion of PCs in plasma were 20.7 +/- 8. 5 and 11.5 +/- 8.0, respectively. CCIs after transfusion of PCs in PAS-2 were significantly lower: the average 1-hour CCI was 17.1 +/- 6.6 (p<0.001) and the average 20-hour CCI was 9.5 +/- 7.0 (p<0.05). Storage conditions of PCs were optimal: in each group, average 1-hour CCIs of both fresh and stored PCs were similar. The 20-hour CCIs after the transfusion of fresh and stored PCs in PAS-2 also were similar.
CONCLUSION: Transfusion of PCs in PAS-2 significantly reduces the incidence of reactions. The 1-hour and 20-hour CCIs after transfusion of PCs in PAS-2 were significantly lower than the CCIs after transfusion of PCs in plasma. Because storage conditions of both PCs were found to be optimal, the decrease in CCIs after transfusion of PCs prepared in PAS-2 may be caused by rapid elimination of a subpopulation of P-selectin-positive platelets from the circulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773049     DOI: 10.1046/j.1537-2995.2000.40040398.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

Review 1.  Scratching the surface of allergic transfusion reactions.

Authors:  William J Savage; Aaron A R Tobian; Jessica H Savage; Robert A Wood; John T Schroeder; Paul M Ness
Journal:  Transfusion       Date:  2012-09-24       Impact factor: 3.157

2.  The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME).

Authors:  Aaron A R Tobian; Alice K Fuller; Kristin Uglik; Daniel J Tisch; Prabhakar D Borge; Richard J Benjamin; Paul M Ness; Karen E King
Journal:  Transfusion       Date:  2013-11-19       Impact factor: 3.157

3.  The impact of apheresis platelet manipulation on corrected count increment.

Authors:  Matthew Karafin; Alice K Fuller; William J Savage; Karen E King; Paul M Ness; Aaron A R Tobian
Journal:  Transfusion       Date:  2012-01-10       Impact factor: 3.157

4.  ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions.

Authors:  Matthew S Karafin; Lorraine Blagg; Aaron A R Tobian; Karen E King; Paul M Ness; William J Savage
Journal:  Transfusion       Date:  2012-02-17       Impact factor: 3.157

5.  Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.

Authors:  Mei Zhu; Wei Xu; Bao-Long Wang; Hong Su
Journal:  Transfus Med Hemother       Date:  2014-05-22       Impact factor: 3.747

6.  The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions.

Authors:  Seema Kacker; Paul M Ness; William J Savage; Kevin D Frick; Jeffrey McCullough; Karen E King; Aaron A R Tobian
Journal:  Transfusion       Date:  2013-01-30       Impact factor: 3.157

Review 7.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon J Stanworth; Carolyn Doree; Sally Hopewell; Marialena Trivella; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-18

Review 8.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Gemma L Crighton; Lise J Estcourt; Erica M Wood; Marialena Trivella; Carolyn Doree; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

Review 9.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Patricia Blanco; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-10-27

Review 10.  Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.

Authors:  Fumiya Hirayama
Journal:  Br J Haematol       Date:  2012-12-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.